Schindler disease is a recently recognized infantile neuroaxonal dystrophy resulting from the deficient activity of the lysosomal hydrolase, a-N-acetylgalctosaminidase (a-GalNAc). The recent isolation and expression of the full-length cDNA encoding a-GalNAc facilitated the identification of the molecular lesions in the affected brothers from family D, the first cases described with this autosomal recessive disease. Southern and Northern hybridization analyses of DNA and RNA from the affected homozygotes revealed a grossly normal aGalNAc gene structure and normal transcript sizes and amounts. Therefore, the a-GalNAc transcript from an affected homozygote was reverse-transcribed, amplified by the polymerase chain reaction (PCR), and sequenced. A single G to A transition at nucleotide 973 was detected in multiple subclones containing the PCR products. This point mutation resulted in a glutamic acid to lysine substitution in residue 325 (E325K) of the a-GalNAc polypeptide. The base substitution was confirmed by dot blot hybridization analyses of PCR-amplified genomic DNA from family members with allele-specific oligonucleotides. Furthermore, transient expression of an a-GalNAc construct containing the E325K mutation resulted in the expression of an immunoreactive polypeptide which had no detectable a-GalNAc activity. (J. Clin. Invest. 1990Invest. .86:1752Invest. -1756
Introduction
Schindler disease is a recently recognized infantile form of neuroaxonal dystrophy resulting from the deficient activity of the lysosomal glycohydrolase, a-N-acetylgalactosaminidase (E.C. 3.2.129; a-GalNAc)' (1-3). The enzymatic defect, inher-ited as an autosomal recessive trait, leads to the tissue accumulation and increased urinary excretion ofglycopeptides and oligosaccharides containing a-N-acetylgalactosaminyl moieties (4, 5) . The disorder was described in two brothers from family D who were the offspring of a consanguineous couple of German descent. The affected infants' development appeared normal for the first 9 to 12 mo ofage. In the second year oflife, they experienced a period of developmental delay which was followed by rapid psychomotor regression. By 3-4 yr of age, the progressive neurologic impairment led to cortical blindness, myoclonic seizures, spasticity, decorticate posturing, and profound psychomotor retardation. A cortical biopsy revealed the presence of"spheroids" in terminal axons, the unique neuropathology which classified this disease as a neuroaxonal dystrophy (2, 6) . These clinical and morphologic manifestations in the two affected brothers were essentially identical to those in patients with Seitelberger disease, an infantile form of neuroaxonal dystrophy (6) ; however, the finding of normal a-GalNAc activity in eight unrelated patients with Seitelberger disease (2) demonstrated that Schindler disease was biochemically distinct and that the infantile neuroaxonal dystrophies were genetically heterogeneous (2) .
The affected homozygotes with Schindler disease had levels of a-GalNAc activity that were less than 1% of normal in various sources as assayed with the recently synthesized substrate, 4-methylumbelliferyl-a-N-acetylgalactosaminide (4MU-a-GalNAc) (2, 7) . Their parents had intermediate levels of activity consistent with being obligate heterozygotes for this autosomal recessive disorder. Using monospecific rabbit antihuman a-GalNAc antibodies, immunoblots of fibroblast extracts from the affected brothers revealed no detectable immunoreactive enzyme protein, while extracts from their parents and a normal brother had two immunoreactive peptide species, the 48-kD monomeric and 117-kD dimeric forms of aGalNAc observed in normal cultured fibroblasts and in preparations of the purified human enzyme (2, 8) . These findings suggested that the a-GalNAc mutation in this family markedly altered the enzyme's activity and stability.
The recent isolation, sequencing, and expression of the full-length cDNA encoding human a-GalNAc (8) permitted investigation of the molecular lesion in the a-GalNAc gene that causes Schindler disease in this consanguineous family. The a-GalNAc cDNA encodes a polypeptide of 411 amino acids including a signal peptide of 17 residues. Studies of human a-GalNAc biosynthesis indicated that the precursor polypeptide was cotranslationally glycosylated in the endoplasmic reticulum, and following carbohydrate modifications and phosphorylation of its high mannose-type oligosaccharide structures in the Golgi, the mature glycopeptide of 394 amino acids was trafficked to the lysosome via the mannose-6-phosphate receptor-mediated pathway (9) . Presumably, the mature glycopeptide is dimerized to form the 11 7-kD active form in the Golgi.
In this communication, we report the specific missense mutation in the a-GalNAc coding region which causes an infantile neuroaxonal dystrophy in this consanguineous family. This base substitution was confirmed by analysis of genomic DNA from family members and by transient expression studies. Of interest was the fact that inactive enzyme protein expressed in COS-1 cells was immunologically detectable, whereas no cross-reacting immunological material (CRIM) was present in cultured fibroblasts from the patients.
Methods
Cell lines. Primary cultures of fibroblasts and lymphoblasts were established from skin biopsies and peripheral blood samples obtained from the family D members with Schindler disease and from normal controls with informed consent. The COS-1 cell lines were obtained from the American Type Culture Collection (Rockville, MD). The fibroblasts, lymphoblasts, and COS-1 cell lines were grown in RPMI 1640 media supplemented with 10% fetal bovine serum, 1% penicillin, and I mg/ml streptomycin by standard procedures (10) .
Assays ofa-GalNAc activity andprotein. The a-GalNAc activity in COS-I cells was determined with the synthetic fluorogenic substrate 4MU-a-GalNAc (7) as previously described (2) . Protein concentration was determined by the fluorescamine assay (11). Immunobolt analyses of a-GalNAc in transfected COS-I cells were performed using monospecific rabbit anti-human antibodies as described (2, 8 (13) , and analyzed using the nick-translated a-GalNAc cDNA as a probe (14) . To determine the relative sizes and amounts of the 2.2-and 3.6-kb a-GalNAc transcripts (8), total RNA was isolated from at least 108 cultured lymphoblasts (15) . RNA samples were electrophoresed in I% agarose/formaldehyde denaturing gels (16), transferred to the BioTrace membranes described above, and analyzed with the radiolabeled a-GalNAc riboprobe synthesized with SP6 polymerase from the a-GalNAc 2.2-kb cDNA cloned into the pGEM 4Z vector (Promega Biotec, Madison, WI).
DNA amplification and sequencing ofthe mutant allele. Sense and antisense oligonucleotide primers designed to amplify the entire coding region of the a-GalNAc gene in two overlapping fragments were synthesized on a model 380B DNA synthesizer (Applied Biosystems, Inc., Foster City, CA). As shown in Fig. 1 (18) . Clones containing the PCR products were identified by plaque hybridization using the nick-translated aGalNAc cDNA (14) . Single-stranded template was isolated (18) from six separate M 13 clones, and each was sequenced in both orientations by the dideoxy chain-termination method (19) using universal and a-GalNAc-specific primers. Oligonucleotide hybridization ofgenomic DNA. Genomic DNAs (1 jig) from affected homozygotes, their obligate heterozygous parents, and normal individuals were PCR-amplified using primers that flanked the region of the mutation by the conditions described above. The 5' sense primer was a 20-mer (5'-TGATGTCCACA-GACCTGCGT-3') corresponding to nt 842-861 and the 3' antisense primer was a 20-mer (5'-TCAGCTGCAGGACCGATATG-3') corresponding to nt 1005-1024 of the a-GaINAc full-length cDNA, pAGB-3 (8). Normal and mutation-specific oligonucleotide probes (2 1-mers) were synthesized with the sequences 5'-TCTCTCATC-GAAGTGTACATG-3' and 5'-TCTCTCATCAAAGTGTACATG-3', respectively. Dot blots were denatured, hybridized, and washed as described (20) .
Computer-assisted analyses. Local secondary structure for both the normal and mutant enzymes were predicted by the algorithms ofChou and Fasman (21) and Gamier et al. (22) using the University of Wisconsin Computer Group software (23). A region of 20 amino acids surrounding the site ofthe glutamic acid to lysine substitution was used for the prediction of the local secondary structure.
Construction ofthe mutant cDNA and transient expression ofthe mutation in CC)S-J cells. A Bam HI-Kpn I fragment containing the G to A substitution from an M 13 clone was used as a cassette to replace the corresponding region in the full-length a-GalNAc cDNA (8) . The sequence of this construct was confirmed by dideoxy sequencing, and then the construction was subcloned into the eukaryotic expression vector p91023(B) (24) kindly provided by Dr. R. J. Kaufmann, Genetics Institute, Cambridge, MA. COS-1 cells were transfected with the mutant construct, designated p91-AGB-973A (25) , harvested at 72 h posttransfection, and then assayed for activity and immunoreactive protein as previously described (2).
Results
Molecular characterization ofthe a-GalNAc mutation in family D. In order to characterize the nature of the mutation in family D, Southern analysis was performed with four restriction endonucleases on genomic DNA from the affected homozygotes, their obligate heterozygous parents, and unrelated normal individuals. No obvious gene rearrangements were observed (data not shown). It is interesting that the family D members were polymorphic at the a-GalNAc locus for two restriction endonuclease sites, Bam HI and Taq I; these polymorphic sites were found in 16 of 40 (45%) and 2 of 76 (2.6%) normal Caucasian alleles, respectively. Northern analysis of total RNA from family D members and from normal individuals revealed the presence of the two a-GalNAc transcripts of 2.2 kb and -3.6 kb. Since the affected brothers had transcripts of normal size and abundancy, the possibility of promotor, mRNA processing, or stability mutations was excluded. These findings, and the fact that no a-GalNAc immunoreactive enzyme protein was detected in fibroblasts from the affected homozygotes, suggested that the mutation causing Schindler disease was most likely due to point mutations or small insertions or deletions in the coding region of the a-GalNAc gene.
To identify the a-GalNAc mutation in this family, total RNA isolated from the cultured lymphoblasts of an affected sibling was reverse transcribed, PCR-amplified, and sequenced in both orientations as described above (Fig. 1) . Sequence analysis of all 12 subclones revealed a G to A transition at nucleotide 973 which caused a glutamic acid to lysine substitution at residue 325 (Fig. 2) . This substitution, designated E325K, was confirmed by hybridization of allele-specific oligonucleotides with PCR-amplified genomic DNA from the affected homozygotes, the obligate heterozygous parents and normal individuals. As shown in Fig. 3 , the mutation-specific oligonuceotide hybridized only with the amplified genomic sequence from the affected homozygotes. In support of this finding, the genomic PCR product from each of their parents hybridized with both the normal and mutation-specific oligonucleotides. Expression ofthe mutation in COS-I cells. To further characterize this mutation, the Bam HI-Kpn I fragment (nt 921-1193) from an Ml 3 subclone containing the mutant allIle was introduced as a cassette into the full-length pAGB-3 cDNA. The mutated cDNA, designated pAGB-973A, was sequenced and then subcloned into the eukaryotic expression vector p91023(B). This expression construct, p91-AGB-973A, was transfected into COS-1 cells, and 72 h after transfection the cells were harvested and extracts were assayed for a-GalNAc activity and immunoreactive enzyme protein. Immunoblot analysis revealed the presence of immunologically detectable protein with a subunit molecular weight of 48 kD (Fig.   4) . However, 4MU-a-GalNAc activity in COS-1 cells was not increased above endogenous COS-1 cell levels, whereas the GalNAc purified from human lung (8) . Note that the expressed normal and mutant a-GalNAc subunits are doublets that appear to have slightly higher molecular weights than the purified enzyme subunit from human lung, presumably due to slightly different glycosylation by COS-I cells. normal construct, p91-AGB-3, expressed immunodetectable protein that had an a-GalNAc activity that was 20-fold greater than the mean endogenous level or the mean level in mocktransfected COS-1 cells (Table I) . Secondary structure analyses. Computer-assisted regional secondary structural analysis of residues 310 to 330 predicted differences in the normal and E325K structures (21, 22) . As illustrated in Fig. 5 , the glutamic acid to lysine substitution in E325K extended a ,-pleated sheet region 5' to the mutation, and created a short a-helical structure which included the mutation.
Discussion
Schindler disease is the only neuroaxonal dystrophy in which the biochemical defect has been identified. Although the deficient a-GalNAc activity results in the lysosomal accumulation and urinary excretion of a-GalNAc-containing oligosaccharides and glycopeptides, the nature of the biochemical alterations in the brain that cause the unique neuroaxonal pathol- (26) . The detection of immunoreactive enzyme in the COS-1 cells most likely reflects the "pulsed" synthesis of the altered human polypeptide that then is degraded due to instability and/or the inability of the polypeptide subunits to associate into more stable multimeric forms. This may be the case for the a-GalNAc polypeptide since the homodimeric form is extremely stable (8) . Thus, the classification of a mutation as CRIM-negative based on studies of the patient's cells or tissues does not imply that the enzyme is not synthesized. Subsequent stable expression of normal and mutant constructs may provide sufficient quantities of these enzyme proteins for comparison of their physical and kinetic properties. For example, such studies may determine if the E325K mutation alters subunit association, the interaction with different substrates, and/or other factors in the catalytic complex.
The identification of this molecular lesion in the family D homozygotes will permit accurate heterozygote detection for relatives using allele-specific oligonucleotides. Molecular heterozygote diagnosis will be particularly valuable since there was significant overlap in the ranges of enzymatic activities in various sources for family D obligate heterozygotes and normal individuals. Moreover, since family D is from a small inbred village in which previous children with the Schindler phenotype were known, screening can be performed to identify carriers and provide the opportunity for accurate prenatal diagnosis, if requested. Although Schindler disease is the only neuroaxonal dystrophy in which the biochemical and molecular defects have been identified, the nature of the accumulated neuronal substrate(s) and the pathophysiologic events that lead to the unique spheroid formations in the distal axons remain unknown. Further studies ofthis disease may provide insight into the normal role of a-Ga1NAc-containing glycoconjugates and a-GalNAc in neuronal metabolism and/or transport.
